Biocartis

Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform.

Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample

in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.*

Biocartis employs approximately 300 people and is headquartered in Mechelen, Belgium. Further information can be found at: www.biocartis.com

* http://www.alliedmarketresearch.com/ivd-in-vitro-diagnostics-market

22/05/2026

𝗪𝗲'𝗿𝗲 𝗵𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝗔𝗦𝗖𝗢! 🚀
📅 29 May - 2 June |📍Booth 18152 | 🗺️ Chicago, IL, US

Join us at booth 𝟭𝟴𝟭𝟱𝟮 to discover how the 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 can deliver molecular biomarker results in 𝗼𝗻𝗹𝘆 𝟯 𝗵𝗼𝘂𝗿𝘀⏱️Because securing targeted answers shouldn't require waiting on NGS....

𝗟𝗲𝘁'𝘀 𝗰𝗼𝗻𝗻𝗲𝗰𝘁 𝗮𝘁 𝗔𝗦𝗖𝗢 👉 𝗕𝗼𝗼𝗸 𝘆𝗼𝘂𝗿 𝗺𝗲𝗲𝘁𝗶𝗻𝗴: https://lnkd.in/eSx8X2ZV

20/05/2026

💡 𝐋𝐞𝐭 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐫𝐞𝐯𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐢𝐳𝐞 𝐭𝐡𝐞 𝐰𝐚𝐲 𝐲𝐨𝐮 𝐰𝐨𝐫𝐤
The Idylla™ Platform is a revolutionary, fully automated, real-time PCR-based molecular testing system designed to offer 𝐦𝐨𝐥𝐞𝐜𝐮𝐥𝐚𝐫 𝐛𝐢𝐨𝐦𝐚𝐫𝐤𝐞𝐫 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 𝐢𝐧 𝐨𝐧𝐥𝐲 𝟑 𝐡𝐨𝐮𝐫𝐬. Accessible on demand and no need for batching. It makes molecular testing 𝐞𝐚𝐬𝐲, 𝐟𝐚𝐬𝐭 𝐚𝐧𝐝 𝐬𝐮𝐢𝐭𝐚𝐛𝐥𝐞 𝐟𝐨𝐫 𝐚𝐧𝐲 𝐥𝐚𝐛.

𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 👉 https://www.biocartis.com/en/meet-idylla/idylla-platform?utm_source=facebook&utm_medium=social&utm_campaign=idylla-platform

Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries.

18/05/2026

𝐈𝐝𝐲𝐥𝐥𝐚™. 𝐁𝐚𝐜𝐤𝐞𝐝 𝐛𝐲 𝟑𝟎𝟎+ 𝐩𝐞𝐞𝐫-𝐫𝐞𝐯𝐢𝐞𝐰𝐞𝐝 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬
The Idylla™ Platform isn’t just fast, it's highly accurate and scientifically proven. With over 300 peer-reviewed publications, Idylla™ demonstrates real-world impact in molecular biomarker testing.

𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫 𝐭𝐡𝐞 𝐥𝐚𝐭𝐞𝐬𝐭 𝐩𝐮𝐛𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬 👉 https://www.biocartis.com/en/meet-idylla/publications?utm_source=facebook&utm_medium=social&utm_campaign=publications

12/05/2026

𝐒𝐩𝐫𝐢𝐧𝐠 𝐭𝐢𝐦𝐞! 𝐓𝐢𝐦𝐞 𝐭𝐨 𝐠𝐞𝐭 𝐭𝐡𝐞 𝐬𝐮𝐧𝐬𝐜𝐫𝐞𝐞𝐧 𝐨𝐮𝐭☀️
May is Melanoma & Skin Cancer Awareness Month, a month in which we take time to raise awareness on preventing and treating skin cancer and melanoma 🖤

Biocartis offers the 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐁𝐑𝐀𝐅 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐓𝐞𝐬𝐭* for patients with advanced melanoma. This Test offers 𝐟𝐮𝐥𝐥𝐲 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝟕 𝐁𝐑𝐀𝐅 𝐦𝐮𝐭𝐚𝐭𝐢𝐨𝐧𝐬 in codon 600 directly from 𝟏 𝐅𝐅𝐏𝐄 𝐭𝐢𝐬𝐬𝐮𝐞 𝐬𝐞𝐜𝐭𝐢𝐨𝐧 👉 https://www.biocartis.com/en/meet-idylla/idylla-oncology-tests/idylla-braf-mutation-test?utm_source=facebook&utm_medium=social&utm_campaign=idylla-braf-mutation-test

*CE-marked in Europe in compliance with the EU IVD Directive 98/79/EC. For Research Use Only (RUO), not for use in diagnostic procedures, in the US.
The Skin Cancer Foundation

11/05/2026

Molecular biomarker results in ONLY 3 HOURS!
💡 THINK IDYLLA™

Today, Biocartis offers tests and assays enabling rapid biomarker results in lung, skin, thyroid, colorectal, endometrial, blood, brain and breast cancer samples.

More information 👉 https://www.biocartis.com/en/meet-idylla?utm_source=facebook&utm_medium=social&utm_campaign=meet-idylla

08/05/2026

📍 𝗘𝗦𝗠𝗢 𝗕𝗿𝗲𝗮𝘀𝘁 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗕𝗲𝗿𝗹𝗶𝗻 – 𝘁𝗵𝗮𝗻𝗸 𝘆𝗼𝘂 𝗳𝗼𝗿 𝗮 𝗴𝗿𝗲𝗮𝘁 𝗲𝘃𝗲𝗻𝘁!
At this year’s conference, Katrijn presented new independent validation data for the 𝗜𝗱𝘆𝗹𝗹𝗮™ 𝗣𝗜𝗞𝟯𝗖𝗔–𝗔𝗞𝗧𝟭 𝗠𝘂𝘁𝗮𝘁𝗶𝗼𝗻 𝗔𝘀𝘀𝗮𝘆* in a retrospective pan-cancer cohort of 313 specimens.

Across all tumor types, 𝗰𝗼𝗻𝗰𝗼𝗿𝗱𝗮𝗻𝗰𝗲 𝘄𝗶𝘁𝗵 𝗡𝗚𝗦 𝗮𝗻𝗱 𝗾𝗣𝗖𝗥 reference methods showed 𝘀𝘁𝗿𝗼𝗻𝗴 𝗽𝗲𝗿𝗳𝗼𝗿𝗺𝗮𝗻𝗰𝗲:
✔️ 95.2% Overall Percentage Agreement (OPA)
✔️ 93.2% Negative Percentage Agreement (NPA)
✔️ 96.7% Positive Percentage Agreement (PPA)

The Idylla™ PIK3CA–AKT1 Mutation Assay detects 13 PIK3CA mutations and 1 AKT1 mutation directly from 𝗙𝗙𝗣𝗘 𝘁𝗶𝘀𝘀𝘂𝗲, enabling 𝗿𝗮𝗽𝗶𝗱, 𝗼𝗻-𝗱𝗲𝗺𝗮𝗻𝗱 molecular testing 𝘄𝗶𝘁𝗵𝗼𝘂𝘁 𝘁𝗵𝗲 𝗻𝗲𝗲𝗱 𝗳𝗼𝗿 𝗯𝗮𝘁𝗰𝗵𝗶𝗻𝗴.

𝗟𝗲𝗮𝗿𝗻 𝗺𝗼𝗿𝗲 👉 https://www.biocartis.com/en/research/research-assays/idylla-pik3ca-akt1-mutation-assay-0

*𝘍𝘰𝘳 𝘙𝘦𝘴𝘦𝘢𝘳𝘤𝘩 𝘜𝘴𝘦 𝘖𝘯𝘭𝘺 (𝘙𝘜𝘖), 𝘯𝘰𝘵 𝘧𝘰𝘳 𝘶𝘴𝘦 𝘪𝘯 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘵𝘪𝘤 𝘱𝘳𝘰𝘤𝘦𝘥𝘶𝘳𝘦𝘴.

06/05/2026

𝟏 𝐏𝐥𝐚𝐭𝐟𝐨𝐫𝐦. 𝟗𝟓+ 𝐜𝐨𝐮𝐧𝐭𝐫𝐢𝐞𝐬. 𝐂𝐨𝐮𝐧𝐭𝐥𝐞𝐬𝐬 𝐝𝐞𝐜𝐢𝐬𝐢𝐨𝐧𝐬 𝐬𝐮𝐩𝐩𝐨𝐫𝐭𝐞𝐝.
The Idylla™ Platform empowers pathologists and oncologists worldwide with fast, reliable molecular biomarker testing. Every day, it helps them make confident, data-driven patient management decisions.

𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 👉 https://www.biocartis.com/en/meet-idylla/idylla-platform?utm_source=facebook&utm_medium=social&utm_campaign=idylla-platform

Idylla™ Platform is CE-marked in Europe in compliance with EU IVD Regulation 2017/746, listed as a class II device in the US under establishment registration 3009972873, and registered in many other countries

04/05/2026

🔬 𝐓𝐨𝐝𝐚𝐲 𝐢𝐬 𝐌𝐞𝐥𝐚𝐧𝐨𝐦𝐚 𝐌𝐨𝐧𝐝𝐚𝐲 — a day to raise awareness about one of the most aggressive forms of skin cancer. At Biocartis, we’re committed to supporting clinicians with fast and reliable tools for informed decision-making in melanoma care.

⚡ The 𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐁𝐑𝐀𝐅 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐓𝐞𝐬𝐭* delivers accurate results in ~ 90 min — directly from 1 FFPE tissue section, with < 3 min hands-on time.
✅ Fully automated sample-to-result workflow
✅ Faster BRAF results for earlier treatment decisions
✅ Actionable insights when time matters most
https://www.biocartis.com/en/meet-idylla/idylla-oncology-tests/idylla-braf-mutation-test?utm_source=facebook&utm_medium=social&utm_campaign=idylla-braf-mutation-test

🎗️ This Melanoma Monday, 𝐁𝐢𝐨𝐜𝐚𝐫𝐭𝐢𝐬 𝐬𝐭𝐚𝐧𝐝𝐬 𝐰𝐢𝐭𝐡 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬, 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐩𝐫𝐨𝐟𝐞𝐬𝐬𝐢𝐨𝐧𝐚𝐥𝐬, 𝐚𝐧𝐝 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐟𝐢𝐠𝐡𝐭 𝐚𝐠𝐚𝐢𝐧𝐬𝐭 𝐬𝐤𝐢𝐧 𝐜𝐚𝐧𝐜𝐞𝐫.

*CE-marked in Europe in compliance with the EU IVD Directive 98/79/EC. For Research Use Only (RUO), not for use in diagnostic procedures, in the US.

30/04/2026

𝐈𝐝𝐲𝐥𝐥𝐚™ 𝐏𝐎𝐋𝐄-𝐏𝐎𝐋𝐃𝟏 𝐌𝐮𝐭𝐚𝐭𝐢𝐨𝐧 𝐀𝐬𝐬𝐚𝐲*
✅ Molecular classification of samples in ~ 95 min.
✅ Covers 99% of the known pathogenic & mutations
✅ Achieved 98.2% accuracy with 450+ endometrial cancer samples (Barault et al., 2024)
✅ Fit for use on small biopsies & directly from 1 FFPE tissue section
✅ No need for sample batching
✅ Straightforward results reporting

👉 𝐑𝐞𝐚𝐝 𝐦𝐨𝐫𝐞 https://lnkd.in/euSnrt5T

*For Research Use Only (RUO), not for use in diagnostic procedures.
Barault, L. et al. (2024). The Idylla™ POLE Mutation Assay, A New Tool For Direct Mutation Detection From FFPE Tissue. AMP 2024 Annual Meeting

28/04/2026

Revolutionize your CRC diagnostics with Idylla™ 🏆

⏱️Speed up your therapy decisions and alleviate patient anxiety*!

Rapidly identify patients eligible for immunotherapy through MSI, and targeted therapy with RAS and BRAF, with results in only three hours. Ensure they receive the most effective treatment without delay.

👉 Read morehttps://www.biocartis.com/sites/default/files/2026-03/CRC%20Oncologist%20-%20Leaflet%20-%20Mar2026.pdf

Your patients, our priority. Guiding them to the right therapy within hours ⚡

*Miles, A. (2018). The Psychological Implications of Diagnostic Delay in Colorectal Cancer Patients. In: Olsson, L. (eds) Timely Diagnosis of Colorectal Cancer. Springer, Cham.
The content of this post is only applicable to Idylla™ KRAS & NRAS-BRAF Mutation Tests and Idylla™ MSI & CDx MSI Tests which are CE-marked in Europe; Idylla™ MSI Test which is cleared in the US under K211181 for Lynch Syndrome; and Idylla™ CDx MSI Test which is approved in the US under P250005. Idylla™ KRAS & NRAS-BRAF Mutation Assays are for Research Use Only (RUO), not for use in diagnostic procedures, in the US.

Adres

Generaal De Wittelaan 11B
Mechelen
2800

Telefoon

+3215632600

Website

http://www.biocartis.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Biocartis nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.